-+ 0.00%
-+ 0.00%
-+ 0.00%
The Zhitong Finance App learned that German private biotech company Disco Pharmaceuticals said on Thursday that ABBV.US (ABBV.US) agreed to pay up to 2.54 billion US dollars to jointly develop cancer treatments with Disco, which marks the pharmaceutical company's early layout for the next generation of bispecific antibody therapy.
Share
Listen to the news
The Zhitong Finance App learned that German private biotech company Disco Pharmaceuticals said on Thursday that ABBV.US (ABBV.US) agreed to pay up to 2.54 billion US dollars to jointly develop cancer treatments with Disco, which marks the pharmaceutical company's early layout for the next generation of bispecific antibody therapy.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending